Accepted but Not Final: How Articles in Press Are Reshaping Scientific Publishing

In the fast-moving world of biomedical research, the gap between a manuscript’s acceptance and its formal publication has long been a source of frustration for scientists, journalists, and clinicians alike. A paper may be peer reviewed, approved, and ready to influence practice, yet sit in a publishing queue for weeks or months while typesetting, proofing, and issue assembly take place. BMC Pharmacology and Toxicology, an open access journal in the Springer Nature portfolio, is one of many journals addressing this bottleneck through a mechanism known as the Article in Press. Under this model, once a manuscript has been formally accepted after peer review, it is published online in an early-access version that carries a permanent Digital Object Identifier, or DOI, and can immediately be viewed, shared, and cited by the research community.

The technical foundation of the Article in Press system rests on the DOI, a persistent alphanumeric string assigned to a scholarly work that resolves through the DOI registry to a stable landing page. Because the DOI is assigned at the point of acceptance rather than at final publication, the early version becomes a citable object in its own right. Other researchers can reference it in their own manuscripts, grant applications, and systematic reviews without waiting for the Version of Record to appear. This matters enormously in fast-moving fields such as pharmacology and toxicology, where findings about drug safety mechanisms, toxicological pathways, or therapeutic targets can have direct implications for ongoing research and, in some cases, clinical decision-making. A citation to an Article in Press resolves to the paper itself, and when the final version replaces the early version, the same DOI continues to point to the most authoritative rendition of the work.

It is important to understand precisely what an Article in Press is and what it is not. The version published at this stage is the accepted, peer-reviewed manuscript, meaning it has passed the scrutiny of expert reviewers and the journal’s editors. However, it has not yet undergone the full production process: professional copyediting, typesetting, author proofing, and final quality checks are still to come. Springer Nature labels these articles clearly online to signal that they are not the final Version of Record, and all legal disclaimers that apply to the journal apply equally to the early version. This labelling is not a bureaucratic formality; it is a transparency mechanism that allows readers to calibrate their confidence appropriately. The scientific content has been validated by peer review, but the presentation, formatting, and fine details may still change.

Indeed, the possibility of change is explicitly acknowledged in the system’s design. Errors affecting the content may be discovered during the final production process, and errors present in the Article in Press version will be corrected during the author proofing stages of production. Those corrections are then reflected in the final Version of Record. In practice, this means that a typographical error in a dose calculation, a mislabelled figure axis, or an inconsistency between the abstract and the results section that slipped past reviewers can be caught and fixed before the paper reaches its definitive form. The author proofing stage gives researchers a final opportunity to review their work in its near-final typeset state and to flag any remaining problems. This layered quality control, combining pre-publication peer review with post-acceptance production checks, reflects the reality that even rigorous review processes cannot catch every imperfection.

When the final Version of Record is published, it replaces the Article in Press, retaining the same DOI. This continuity is one of the most elegant aspects of the system. Unlike a preprint posted on a server such as arXiv or bioRxiv, which typically remains a separate, parallel object alongside the journal version, the Article in Press is a stage within the journal’s own publication pipeline. There is no ambiguity about which version is authoritative: the Version of Record supersedes the early version at the same persistent address. For librarians, database indexers, and citation managers, this simplifies the scholarly record. For readers who encounter a citation months later, the DOI leads to the final, corrected, typeset article rather than to a frozen early draft.

The Article in Press model is closely tied to the economics and philosophy of open access publishing. Fully open access journals in the Springer Nature portfolio provide this service on every accepted manuscript, meaning that no accepted paper waits in limbo. In the traditional subscription model, early access was sometimes offered as a premium service or limited to certain article types, but open access journals, which cover their costs through article processing charges rather than subscriptions, have little incentive to delay visibility. The speed of dissemination serves the public good: pharmacological and toxicological findings, including those relevant to drug safety, environmental exposures, and therapeutic development, reach the widest possible audience as quickly as the review process allows. For researchers in low- and middle-income countries, in particular, immediate open availability of accepted manuscripts removes a significant barrier to staying current with the literature.

The implications extend beyond academia into science communication and public health. Journalists and press officers who monitor the pharmacology and toxicology literature can report on significant findings as soon as they are accepted, rather than waiting for an issue date that may be arbitrary from a news perspective. Springer Nature explicitly encourages authors who are organising a press release for their Article in Press to contact their production editor as early as possible, ensuring that publicity efforts are coordinated with the production timeline. This coordination is more than administrative housekeeping. When a study on a novel drug interaction or an emerging toxicological hazard attracts media attention, accurate reporting depends on journalists having access to a stable, citable version of the paper, and on the authors and journal being prepared to answer questions while the final version is still in production.

Of course, the early-access model also demands a degree of sophistication from its users. Readers must notice the Article in Press label and understand its meaning: the work is peer reviewed and citable, but not yet in its final form. Authors citing an early version should be aware that page numbers, volume, and issue assignments may not yet exist, and citation practices for such versions typically rely on the DOI alone. Reviewers and meta-analysts extracting quantitative data should recognise that corrections made during proofing could, in rare cases, alter numerical details. These caveats are minor compared with the alternative, which is delayed access to validated findings, but they illustrate a broader truth about modern scholarly communication: the once-clean boundary between published and unpublished work has become a spectrum, and every participant in the ecosystem, from authors to readers to journalists, must understand where on that spectrum a given document sits.

The broader trend that the Article in Press exemplifies is the accelerating tempo of scientific publication. Peer review remains the gatekeeping institution of credible science, but the infrastructure surrounding it has been rebuilt for speed and persistence. Persistent identifiers, open licensing, continuous publication, and versioned records together form an architecture in which the traditional journal issue is increasingly a packaging convention rather than the moment of discovery. For a field like pharmacology and toxicology, where the distance between a laboratory finding and a real-world consequence can be short, this architecture is not a luxury. It is part of the safety system itself, ensuring that evidence about efficacy and harm moves as quickly as the molecules it describes. As more journals adopt fully open access models and publish every accepted manuscript immediately, the Article in Press will likely fade from being a noteworthy feature to simply being the norm, the quiet default state of a scientific record that is always in motion.

Subject of Research: Early-access publishing of peer-reviewed manuscripts as Articles in Press in open access pharmacology and toxicology journals

Article Title: Articles in Press

Article References: Articles in Press. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Articles in Press, open access, peer review, Digital Object Identifier, BMC Pharmacology and Toxicology, Springer Nature, Version of Record, scholarly publishing, author proofing, scientific communication, citation, manuscript acceptance